NEWSROOM Press Releases

    254 Results

    Biodesix’ Proteomic Analysis of Innovative Immunotherapy Clinical Trial in Pancreas Cancer presented at European Society of Medical Oncology’s (ESMO) World Congress on Gastrointestinal Cancer

    The first presentation of data resulting from a corporate partnership to explore development of a new diagnostic test based on Biodesix’ technology.

    Biodesix Closes Series D Financing - July 2011

    Biodesix has closed a $20 million series D financing. The new capital will support ongoing commercialization activities for the company's Veristrat.

    Lung Cancer Study Evaluating Changes in VeriStrat Status over the Course of Treatment with Gefitinib Published in Journal of Thoracic Oncology

    Publication announced today: Changes in plasma mass-spectral (VeriStrat) profile in course of treatment of NSCLC patients with EGFR-TKIs.

    Biodesix Announces New VeriStrat® Data to be Presented at the 34th Annual CTRC-AACR San Antonio Breast Cancer Symposium

    A retrospective analysis of serum samples from the phase III study, EGF30008, will be presented at the 34th Annual San Antonio Breast Cancer Symposium SABCS.

    Biodesix’ Paul Beresford Joins 2012 BIO Panel for Personalized Medicine Commercialization

    Biodesix’ Paul Beresford will join industry veterans on a panel discussing the recipe for the successful commercialization of personalized medicine.

    Biodesix Receives 2011 North American Cancer Diagnostics Product Differentiation Excellence Award

    Biodesix received the Product Differentiation Excellence Award for its accomplishments in the cancer diagnostics industry.

    Biodesix Receives New EU and US Patents for Blood-based Oncology Tests

    Biodesix announced the issuance of three additional patents. Two which provide intellectual property protection and the other for Veristrat.

    VeriStrat® Test Results Correlate with Survival Outcomes in Advanced Lung Cancer

    VeriStrat test was able to identify patients likely to have better and worse survival outcomes when treated with the combination therapy.

    Biodesix to Work with Concentra and Hooper Holmes to Expand Access to VeriStrat®

    The initiation of two strategic partnerships that will provide cancer patients greater and more convenient options for completing VeriStrat testing.

    Biodesix Announces Phase 3 Clinical Trial Collaboration with Kadmon

    Biodesix today announced a collaboration with Kadmon Corporation, LLC, to explore the utility of Biodesix’ VeriStrat® test in a Phase 3 (NSCLC).